![101831-37-2 | Diclazuril | 2,6-Dichloro-α-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-benzeneacetonitrile; Clinacox; Nuoqiu; P 64433; R 64433; Vecoxan; | C₁₇H₉Cl₃N₄O₂ | TRC 101831-37-2 | Diclazuril | 2,6-Dichloro-α-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-benzeneacetonitrile; Clinacox; Nuoqiu; P 64433; R 64433; Vecoxan; | C₁₇H₉Cl₃N₄O₂ | TRC](https://www.trc-canada.com/prod-img/D436200.png)
101831-37-2 | Diclazuril | 2,6-Dichloro-α-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-benzeneacetonitrile; Clinacox; Nuoqiu; P 64433; R 64433; Vecoxan; | C₁₇H₉Cl₃N₄O₂ | TRC
![Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects - Kelly Kuk, Jennifer L. Taylor-Cousar, 2015 Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects - Kelly Kuk, Jennifer L. Taylor-Cousar, 2015](https://journals.sagepub.com/cms/10.1177/1753465815601934/asset/images/large/10.1177_1753465815601934-fig2.jpeg)
Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects - Kelly Kuk, Jennifer L. Taylor-Cousar, 2015
![Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure–Activity and Structure–Property Relationship Studies | Journal of Medicinal Chemistry Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure–Activity and Structure–Property Relationship Studies | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.7b00738/asset/images/medium/jm-2017-00738v_0012.gif)
Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure–Activity and Structure–Property Relationship Studies | Journal of Medicinal Chemistry
The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients | PLOS ONE
![Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects - Kelly Kuk, Jennifer L. Taylor-Cousar, 2015 Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects - Kelly Kuk, Jennifer L. Taylor-Cousar, 2015](https://journals.sagepub.com/cms/10.1177/1753465815601934/asset/images/large/10.1177_1753465815601934-fig3.jpeg)
Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects - Kelly Kuk, Jennifer L. Taylor-Cousar, 2015
The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements | PLOS ONE
![Frontiers | Comprehensive Analysis of Chemical Structures That Have Been Tested as CFTR Activating Substances in a Publicly Available Database CandActCFTR Frontiers | Comprehensive Analysis of Chemical Structures That Have Been Tested as CFTR Activating Substances in a Publicly Available Database CandActCFTR](https://www.frontiersin.org/files/Articles/689205/fphar-12-689205-HTML/image_m/fphar-12-689205-g004.jpg)
Frontiers | Comprehensive Analysis of Chemical Structures That Have Been Tested as CFTR Activating Substances in a Publicly Available Database CandActCFTR
![Glycemia and β-cell function before and after elexacaftor/tezacaftor/ ivacaftor in youth and adults with cystic fibrosis - ScienceDirect Glycemia and β-cell function before and after elexacaftor/tezacaftor/ ivacaftor in youth and adults with cystic fibrosis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2214623722000199-gr1.jpg)